Marker Therapeutics, Inc. (NASDAQ:MRKR) to Post FY2023 Earnings of ($0.34) Per Share, Cantor Fitzgerald Forecasts

Marker Therapeutics, Inc. (NASDAQ:MRKRGet Rating) – Cantor Fitzgerald issued their FY2023 EPS estimates for Marker Therapeutics in a note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.34) for the year.

MRKR has been the subject of several other reports. Zacks Investment Research raised Marker Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a research report on Wednesday, June 1st. Roth Capital downgraded Marker Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price target for the company. in a report on Thursday, February 17th. Finally, Piper Sandler decreased their target price on Marker Therapeutics from $3.50 to $1.50 in a report on Friday, May 27th.

Shares of MRKR stock opened at $0.30 on Thursday. The company’s 50 day moving average is $0.35 and its 200 day moving average is $0.60. The firm has a market cap of $25.00 million, a price-to-earnings ratio of -0.58 and a beta of 1.50. Marker Therapeutics has a 52-week low of $0.26 and a 52-week high of $3.65.

Marker Therapeutics (NASDAQ:MRKRGet Rating) last released its quarterly earnings data on Friday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The company had revenue of $0.96 million during the quarter.

Institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in Marker Therapeutics by 1.6% during the third quarter. Geode Capital Management LLC now owns 555,745 shares of the company’s stock valued at $939,000 after buying an additional 8,896 shares during the period. ACT Capital L.L.C. raised its stake in Marker Therapeutics by 4.6% during the third quarter. ACT Capital L.L.C. now owns 439,400 shares of the company’s stock worth $743,000 after purchasing an additional 19,400 shares during the period. D. E. Shaw & Co. Inc. lifted its stake in Marker Therapeutics by 6.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 483,385 shares of the company’s stock worth $459,000 after acquiring an additional 27,343 shares in the last quarter. Wedbush Securities Inc. increased its stake in Marker Therapeutics by 44.0% during the first quarter. Wedbush Securities Inc. now owns 90,068 shares of the company’s stock worth $40,000 after purchasing an additional 27,500 shares during the period. Finally, Morgan Stanley boosted its stake in shares of Marker Therapeutics by 233.5% in the second quarter. Morgan Stanley now owns 51,225 shares of the company’s stock valued at $143,000 after purchasing an additional 35,865 shares during the period. 31.83% of the stock is currently owned by hedge funds and other institutional investors.

About Marker Therapeutics (Get Rating)

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens.

Read More

Earnings History and Estimates for Marker Therapeutics (NASDAQ:MRKR)

Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.